{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T17:42:36Z","timestamp":1791308556247,"version":"4.3.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.jhep.2020.08.006","type":"journal-article","created":{"date-parts":[[2020,8,7]],"date-time":"2020-08-07T02:49:47Z","timestamp":1596768587000},"page":"1548-1556","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":105,"title":["Hepatic benefits of HCV cure"],"prefix":"10.1016","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0287-1059","authenticated-orcid":false,"given":"Vincenza","family":"Calvaruso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Crax\u00ec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2020.08.006_bib1","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.jhep.2018.03.026","article-title":"EASL recommendations on treatment of hepatitis C 2018","volume":"69","author":"Pawlotsky","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.08.006_bib2","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1053\/j.gastro.2018.10.033","article-title":"What are the benefits of a sustained virologic response to direct-acting antiviral therapy for hepatitis C virus infection?","volume":"156","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2020.08.006_bib3","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1053\/j.gastro.2015.08.035","article-title":"Extrahepatic morbidity and mortality of chronic hepatitis C","volume":"149","author":"Negro","year":"2015","journal-title":"Gastroenterology"},{"issue":"Suppl 1","key":"10.1016\/j.jhep.2020.08.006_bib4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/liv.13011","article-title":"Why do I treat my patients with mild hepatitis C","volume":"36","author":"Calvaruso","year":"2016","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhep.2020.08.006_bib5","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.jhep.2013.11.009","article-title":"Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients","volume":"60","author":"Younossi","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2020.08.006_bib6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.7326\/M14-1336","article-title":"Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States","volume":"162","author":"Chhatwal","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jhep.2020.08.006_bib7","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/jvh.13280","article-title":"Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-results from the German Hepatitis C-Registry","volume":"27","author":"Knop","year":"2020","journal-title":"J\u00a0Viral Hepat"},{"issue":"3","key":"10.1016\/j.jhep.2020.08.006_bib8","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/hep.29811","article-title":"Direct-acting antiviral sustained virologic response: impact on mortality in patients without advanced liver disease","volume":"68","author":"Backus","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.08.006_bib9","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemicaloutcomes after successful HCV therapy","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jhep.2020.08.006_bib10","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1002\/hep.25606","article-title":"A\u00a0morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis","volume":"56","author":"D'Ambrosio","year":"2012","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jhep.2020.08.006_bib11","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/liv.13256","article-title":"Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index","volume":"37","author":"Bachofner","year":"2017","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.jhep.2020.08.006_bib12","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.jhep.2019.10.005","article-title":"Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals","volume":"72","author":"Pons","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2020.08.006_bib13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.jhep.2020.08.006_bib14","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1053\/j.gastro.2017.07.016","article-title":"Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis","volume":"153","author":"Lens","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.jhep.2020.08.006_bib15","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/hep.30885","article-title":"Changes in hepatic venous pressure gradient predict hepatic decompensation in patients who achieved sustained virologic\u00a0response to interferon-free therapy","volume":"71","author":"Mandorfer","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jhep.2020.08.006_bib16","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1053\/j.gastro.2018.11.053","article-title":"Validation of Baveno VI criteria for screening and surveillance of esophageal varices in patients with compensated cirrhosis and a sustained\u00a0response to antiviral therapy","volume":"156","author":"Thabut","year":"2019","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2020.08.006_bib17","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00535-019-01619-0","article-title":"Impact of sustained virological response with DAAs on gastroesophageal varices and Baveno criteria in HCV-cirrhotic patients","volume":"55","author":"Puigveh\u00ed","year":"2020","journal-title":"J\u00a0Gastroenterol"},{"issue":"1","key":"10.1016\/j.jhep.2020.08.006_bib18","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1053\/j.gastro.2016.03.036","article-title":"Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension","volume":"151","author":"Di Marco","year":"2016","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.jhep.2020.08.006_bib19","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","article-title":"Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications","volume":"152","author":"Nahon","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.08.006_bib20","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(18)32111-1","article-title":"Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study","volume":"393","author":"Carrat","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2020.08.006_bib21","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.cgh.2020.02.044","article-title":"Disease progression in patients with hepatitis C virus infection treated with direct-acting antiviral agents","volume":"18","author":"Mendizabal","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.jhep.2020.08.006_bib22","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1016\/S0168-8278(18)30385-4","article-title":"Disease outcomes after DAA-induced SVR: data from the resist-HCV cohort","volume":"68","author":"Calvaruso","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2020.08.006_bib23","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib24","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellularcarcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib25","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jhep.2017.08.030","article-title":"HCV eradication induced by direct-acting antiviral agents reduces the risk of hepatocellular carcinoma","volume":"68","author":"Ioannou","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib26","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","article-title":"Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents","volume":"153","author":"Kanwal","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.08.006_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/hep.30823","article-title":"Long-term risk of hepatocellular carcinoma in HCV patients treated with direct acting antiviral agents","volume":"7","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2020.08.006_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jhep.2020.08.006_bib29","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2019.07.033","article-title":"Increased risk for hepatocellular carcinoma persists up to 10 Years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores","volume":"157","author":"Ioannou","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2020.08.006_bib30","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jhep.2019.01.005","article-title":"Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: relevance of non-characterized nodules","volume":"70","author":"Mari\u00f1o","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib31","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","article-title":"Incidence of hepatocellular carcinoma after direct antiviral therapy for HCV in patients with cirrhosis included in surveillance programs","volume":"155","author":"Nahon","year":"2018","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jhep.2020.08.006_bib32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/hep.29408","article-title":"Impact of sustained virologic response with direct-acting antiviral treatment on mortality in patients with advanced liver disease","volume":"69","author":"Backus","year":"2019","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.jhep.2020.08.006_bib33","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jhep.2017.12.019","article-title":"Impact of comorbidities on patient outcomes after interferon-free therapy-induced viral eradication in hepatitis C","volume":"68","author":"Ampuero","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib34","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1056\/NEJMoa1512614","article-title":"Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis","volume":"373","author":"Curry","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jhep.2020.08.006_bib35","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.jhep.2020.08.006_bib36","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","article-title":"Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis","volume":"65","author":"Cheung","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/apt.14404","article-title":"Sofosbuvir and daclatasvir therapy in patients with hepatitis C-related advanced decompensated liver disease (MELD \u2265 15)","volume":"47","author":"McCaughan","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.jhep.2020.08.006_bib38","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41598-018-36734-0","article-title":"Daclatasvir-based regimens in HCV cirrhosis: experience from the Italian early access program","volume":"9","author":"Calvaruso","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.jhep.2020.08.006_bib39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s12072-018-9914-6","article-title":"Treatment with direct-acting antivirals improves the clinical outcome in patients with HCV-related decompensated cirrhosis: results from an Italian real-life cohort (Liver Network Activity-LINA cohort)","volume":"13","author":"Gentile","year":"2019","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2020.08.006_bib40","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.jhep.2020.03.031","article-title":"DAA therapy and long-term hepatic function in advanced\/decompensated cirrhosis: realworld experience from HCV-TARGET cohort","volume":"73","author":"Verna","year":"2020","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.jhep.2020.08.006_bib41","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/j.jhep.2016.05.010","article-title":"Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study","volume":"65","author":"Belli","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2020.08.006_bib42","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1016\/j.jhep.2017.08.008","article-title":"Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation","volume":"67","author":"Pascasio","year":"2017","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2020.08.006_bib43","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/apt.15296","article-title":"The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis","volume":"50","author":"Mecci","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jhep.2020.08.006_bib44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1053\/j.gastro.2018.04.008","article-title":"Incidence of hepatocellular carcinoma in patients with HCV-associated cirrhosis treated with direct-acting antiviral agents","volume":"155","author":"Calvaruso","year":"2018","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.jhep.2020.08.006_bib45","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1111\/liv.13421","article-title":"Hepatocellular carcinoma and direct-acting antivirals: a never ending story?","volume":"37","author":"Calvaruso","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2020.08.006_bib46","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts","volume":"65","author":"Pol","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib47","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1111\/liv.13456","article-title":"Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C","volume":"37","author":"Virlogeux","year":"2017","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.jhep.2020.08.006_bib48","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1111\/apt.14256","article-title":"Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study","volume":"46","author":"Cabibbo","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.jhep.2020.08.006_bib49","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.dld.2018.10.014","article-title":"Predictors of hepatocellular carcinoma in HCV cirrhotic patients treated with direct acting antivirals","volume":"51","author":"Lleo","year":"2019","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jhep.2020.08.006_bib50","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","article-title":"Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: a systematic review, meta-analyses, and meta-regression","volume":"67","author":"Waziry","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2020.08.006_bib51","first-page":"1","article-title":"Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy","volume":"00","author":"Saraiya","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2020.08.006_bib52","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/cam4.2061","article-title":"Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study","volume":"8","author":"Nakano","year":"2019","journal-title":"Cancer Med"},{"issue":"2","key":"10.1016\/j.jhep.2020.08.006_bib53","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/j.jhep.2019.03.027","article-title":"Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients","volume":"71","author":"Cabibbo","year":"2019","journal-title":"J\u00a0Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820305304?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827820305304?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:42:31Z","timestamp":1759174951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827820305304"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0168827820305304"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2020.08.006","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hepatic benefits of HCV cure","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2020.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}